This company is no longer active
Resumen de acción BOTHE
Bone Therapeutics SA, a biotechnology company, engages in the development of cell therapy products for orthopedics and bone diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 2 riesgos adicionales
Competidores de Bone Therapeutics SA
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €0.14 |
| 52 Week High | €1.43 |
| 52 Week Low | €0.12 |
| Beta | 0.30 |
| 1 Month Change | -30.39% |
| 3 Month Change | -41.83% |
| 1 Year Change | -89.97% |
| 3 Year Change | -95.71% |
| 5 Year Change | -98.55% |
| Change since IPO | -99.10% |
Noticias y actualizaciones recientes
Rentabilidad de los accionistas
| BOTHE | BE Biotechs | Mercado BE | |
|---|---|---|---|
| 7D | -6.8% | 1.0% | -0.3% |
| 1Y | -90.0% | -10.3% | -2.4% |
Rentabilidad vs. Industria: BOTHE underperformed the Belgian Biotechs industry which returned -22.9% over the past year.
Rentabilidad vs. Mercado: BOTHE underperformed the Belgian Market which returned -16% over the past year.
Volatilidad de los precios
| BOTHE volatility | |
|---|---|
| BOTHE Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in BE Market | 7.6% |
| 10% least volatile stocks in BE Market | 2.5% |
Precio estable de las acciones: BOTHE's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: BOTHE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2006 | 20 | Miguel Forte | www.bonetherapeutics.com |
Resumen de fundamentos de Bone Therapeutics SA
| Estadísticas fundamentales de BOTHE | |
|---|---|
| Capitalización bursátil | €3.42m |
| Beneficios(TTM) | -€10.07m |
| Ingresos (TTM) | €1.93m |
1.8x
Ratio precio-ventas (PS)-0.3x
Ratio precio-beneficio (PE)¿Está BOTHE sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de BOTHE | |
|---|---|
| Ingresos | €1.93m |
| Coste de los ingresos | €0 |
| Beneficio bruto | €1.93m |
| Otros gastos | €12.00m |
| Beneficios | -€10.07m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
Oct 25, 2022
| Beneficios por acción (BPA) | -0.42 |
| Margen bruto | 100.00% |
| Margen de beneficio neto | -521.82% |
| Ratio deuda/patrimonio | -194.0% |
¿Cómo se ha desempeñado BOTHE a largo plazo?
Ver rendimiento histórico y comparativa